Risvutatug rezetecan for advanced sarcoma that has returned or not responded to earlier treatment
Tests risvutatug rezetecan in people with osteosarcoma or soft tissue sarcoma.
Key facts
- Who runs it
- Glaxosmithkline Research & Development Limited
- Where
- Bordeaux, Lyon, and Villejuif, FranceSee the 3 sites
- Trial code
- Registry title
- A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 14 people, planned
- Started
- 29 Jun 2026
- Expected to end
- 17 Dec 2029
- Type of study
- Interventional
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 to 64 with sarcoma that cannot be removed by surgery and has spread or come back. Cohort 1 is for osteosarcoma and Cohort 2 for soft tissue sarcoma.
- Age
- 12 to 64 years
- Sex
- All sexes
- Disease stage
- Osteosarcoma that came back or did not respond to treatment (Cohort 1), or soft tissue sarcoma (Cohort 2). Either must be advanced or spread, cannot be removed by surgery, and be confirmed under the microscope.
- Earlier treatment
- Must have had at least one earlier line of systemic treatment, and the disease must have grown during or after the last one. Cannot have had an antibody-drug conjugate (ADC) with a TOPO1-inhibitor payload.
Main reasons for not taking part
- Earlier treatment with an ADC with a TOPO1-inhibitor payload
- Severe, uncontrolled or active heart or blood vessel disease
- Active infection needing systemic treatment, or known HIV
- Brain metastases with symptoms, or spread to the brain or spinal cord linings or spinal cord
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participants must be ≥ 12 years of age
- Has histologically confirmed unresectable advanced or metastatic R/R OSA (Cohort 1) or unresectable advanced or metastatic STS (Cohort 2) that has progressed to at least one prior line of systemic therapy
- Has documented disease progression on the last line of systemic treatment as confirmed by radiological imaging; Has an ECOG performance status of 0 or 1, or Lansky PS/Karnofsky PS ≥ 70% for adolescent participants, with no deterioration in the 2 weeks prior to first dose/randomization
- Has adequate organ function
- All participants, or their legal guardians, must provide signed informed consent and agree to follow the study protocol before starting any study activities
Who cannot take part
- Has received any prior therapy with an Antibody-drugconjugates (ADC) with a TOPO1-inhibitor payload; "• Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study."
- Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV); "• Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases."
- Has received treatment with an investigational agent within 4 weeks of the first dose of study intervention
- Has severe, uncontrolled or active cardiovascular disorders
- Is pregnant or breastfeeding
Where in France
- Institut BergonieBordeaux, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- Institut Gustave RoussyVillejuif, FranceTaking people
About the trial
What the trial wants to find out
• To evaluate clinical efficacy of Ris-Rez in participants with unresectable Relapsed/refractory (R/R) Osteosarcoma (OSA) (Cohort 1) who have progressed after or are intolerant to at least one prior line of systemic therapy.
Read full original descriptionShow less
• To evaluate clinical efficacy of Ris-Rez in participants with unresectable advanced or metastatic Soft tissue sarcoma (STS) (Cohort 2) who have progressed after or are intolerant to at least one prior line of systemic therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas
- Plain-language title
- Risvutatug rezetecan for advanced sarcoma that has returned or not responded to earlier treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 July 2026